IPO News | Immvira Bioscience Files for Hong Kong Listing

Stock News01-15

According to a disclosure by the Hong Kong Stock Exchange on January 14, Immvira Bioscience Inc. (Immvira) has submitted an application for a main board listing, with Citigroup and China International Capital Corporation (CICC) acting as its joint sponsors. It is reported that Immvira had previously filed for a main board listing on June 25, 2025.

The prospectus reveals that Immvira is a clinical needs-oriented biotech company dedicated to the discovery, development, manufacturing, and commercialization of novel oncolytic immunotherapies and engineered exosome therapies. The company has established a product pipeline, which includes: (i) two oncolytic immunotherapy products targeting solid tumors, and (ii) five engineered exosome products with promising clinical application potential or that are directly ready for commercialization.

The company's self-developed core product, MVR-T3011, is a Phase II-stage, novel oncolytic immunotherapy product based on the herpes simplex virus type 1 (HSV-1) platform. It combines potent tumor-lytic effects with the expression of an anti-PD-1 antibody and IL-12.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197955311?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 06:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197955311","market":"sg","top_or_hot":-1,"title":"IPO News | Immvira Bioscience Files for Hong Kong Listing","media":"Stock News","content":"<p>According to a disclosure by the Hong Kong Stock Exchange on January 14, Immvira Bioscience Inc. (Immvira) has submitted an application for a main board listing, with Citigroup and China International Capital Corporation (CICC) acting as its joint sponsors. It is reported that Immvira had previously filed for a main board listing on June 25, 2025.</p>\n<p>The prospectus reveals that Immvira is a clinical needs-oriented biotech company dedicated to the discovery, development, manufacturing, and commercialization of novel oncolytic immunotherapies and engineered exosome therapies. The company has established a product pipeline, which includes: (i) two oncolytic immunotherapy products targeting solid tumors, and (ii) five engineered exosome products with promising clinical application potential or that are directly ready for commercialization.</p>\n<p>The company's self-developed core product, MVR-T3011, is a Phase II-stage, novel oncolytic immunotherapy product based on the herpes simplex virus type 1 (HSV-1) platform. It combines potent tumor-lytic effects with the expression of an anti-PD-1 antibody and IL-12.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO News | Immvira Bioscience Files for Hong Kong Listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO News | Immvira Bioscience Files for Hong Kong Listing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-15 06:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to a disclosure by the Hong Kong Stock Exchange on January 14, Immvira Bioscience Inc. (Immvira) has submitted an application for a main board listing, with Citigroup and China International Capital Corporation (CICC) acting as its joint sponsors. It is reported that Immvira had previously filed for a main board listing on June 25, 2025.</p>\n<p>The prospectus reveals that Immvira is a clinical needs-oriented biotech company dedicated to the discovery, development, manufacturing, and commercialization of novel oncolytic immunotherapies and engineered exosome therapies. The company has established a product pipeline, which includes: (i) two oncolytic immunotherapy products targeting solid tumors, and (ii) five engineered exosome products with promising clinical application potential or that are directly ready for commercialization.</p>\n<p>The company's self-developed core product, MVR-T3011, is a Phase II-stage, novel oncolytic immunotherapy product based on the herpes simplex virus type 1 (HSV-1) platform. It combines potent tumor-lytic effects with the expression of an anti-PD-1 antibody and IL-12.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1197955311","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197955311","pubTimestamp":1768430794,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to a disclosure by the Hong Kong Stock Exchange on January 14, Immvira Bioscience Inc. (Immvira) has submitted an application for a main board listing, with Citigroup and China...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1515":"抗疫概念","BK1161":"生物科技","09939":"开拓药业-B","BK1574":"生物医药B类股"},"translate_title":"IPO快讯|Immvira Bioscience申请香港上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"HEXmain":1,"09939":1},"content_text":"According to a disclosure by the Hong Kong Stock Exchange on January 14, Immvira Bioscience Inc. (Immvira) has submitted an application for a main board listing, with Citigroup and China International Capital Corporation (CICC) acting as its joint sponsors. It is reported that Immvira had previously filed for a main board listing on June 25, 2025.\nThe prospectus reveals that Immvira is a clinical needs-oriented biotech company dedicated to the discovery, development, manufacturing, and commercialization of novel oncolytic immunotherapies and engineered exosome therapies. The company has established a product pipeline, which includes: (i) two oncolytic immunotherapy products targeting solid tumors, and (ii) five engineered exosome products with promising clinical application potential or that are directly ready for commercialization.\nThe company's self-developed core product, MVR-T3011, is a Phase II-stage, novel oncolytic immunotherapy product based on the herpes simplex virus type 1 (HSV-1) platform. It combines potent tumor-lytic effects with the expression of an anti-PD-1 antibody and IL-12.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197955311","isCrawlerRequest":true}